TCT-190 Dabigatran versus Warfarin for stroke prevention in Patients with Atrial Fibrillation: A Post-Hoc Analysis of RE-LY Correlating Body Mass Index with Outcome According to BMI Quintiles

Autor:	Mark I. Jacobs, Michael D. Ezekowitz, Javier E. Arce, Thomas McAndrew, Lars Wallentin
Rok vydání:	2017
Předmět:	medicine.medical_specialty business.industry Warfarin Atrial fibrillation medicine.disease Dabigatran Stroke prevention Internal medicine Post-hoc analysis Cardiology medicine In patient Augment Cardiology and Cardiovascular Medicine business Body mass index medicine.drug
Zdroj:	Journal of the American College of Cardiology. 70:B81
ISSN:	0735-1097
DOI:	10.1016/j.jacc.2017.09.261
Popis:	Dabigatran was shown effective for stroke prevention in atrial fibrillation (AF) in the RE-LY trial. Many pharmaceuticals are dosed according to body weight. We have previously shown the effect of Body Mass Index (BMI) on outcomes using BMI as a continuous variable. We augment that analysis by
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c49f6fc2126dd7646786b3256d422722 https://doi.org/10.1016/j.jacc.2017.09.261 Zobrazit plný text záznamu